Is there an age limit for Mounjaro in the UK?

Why is Mounjaro not licensed below age 18?

The clinical trials that led to Mounjaro's UK approval (including SURMOUNT-1, published in the New England Journal of Medicine) enrolled adults only. Because the safety and efficacy data covers adults, the UK licence reflects that evidence base. The Medicines and Healthcare products Regulatory Agency (MHRA) grants a licence on what the trial programme has demonstrated; extending it to children or adolescents would require a separate paediatric study programme, which has not been conducted for tirzepatide's weight-management indication. That is the reason regulators draw the line at 18, not an assumption about whether younger people might benefit.

In practice this means that any pharmacy supplying Mounjaro to someone under 18 would be operating outside the terms of the UK marketing authorisation. Reputable, GPhC-registered pharmacies verify identity precisely to catch this. If you are researching options for a teenager struggling with weight, the right starting point is a GP referral to a paediatric specialist service rather than any injectable medicine currently on the market.

The dedicated eligibility page sets out the full licensing criteria, including BMI thresholds and weight-related conditions that factor into clinical decisions.

Does being older than 65 change whether Mounjaro is suitable?

There is no upper age cut-off in Mounjaro's UK licence. That said, older adults tend to have more complex medical histories: more medicines, more comorbidities, and physiological changes that affect how drugs are processed. A prescriber will look carefully at kidney function, existing cardiovascular conditions, and any medicines that might interact with tirzepatide before issuing a prescription.

The gastrointestinal side effects (nausea, reduced appetite, loose stools) can carry a higher risk of dehydration in older patients, particularly those already on diuretics or with compromised kidney function. None of this makes Mounjaro automatically unsuitable for someone in their 60s, 70s or beyond, but it does mean the clinical conversation needs to be thorough. Keeping the pen in the fridge door as a daily visual cue matters too, since consistent storage at 2–8°C is required and the SmPC sets the exact room-temperature window if refrigeration is briefly interrupted.

Our prescribers at nume's clinical team review the whole picture (current medicines, health conditions, and weight-related risks) before any approval decision is made. A question about drug interactions with existing tablets is one our team fields regularly from patients in their 50s and 60s.

What actually determines whether someone qualifies, if not age alone?

For weight management, the UK-licensed eligibility criteria centre on BMI and health status. Adults with a BMI of 30 kg/m² or above qualify on BMI grounds; those with a BMI of 27–29.9 kg/m² may also be eligible if they have at least one weight-related condition, for example, high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, as noted in NICE's technology appraisal of tirzepatide (TA1026).

Beyond BMI, a prescriber will check for contraindications: a personal or family history of medullary thyroid carcinoma, a condition called MEN2, or a history of pancreatitis would all require careful consideration. Pregnancy, breastfeeding, and actively trying to conceive are situations where Mounjaro is not recommended. The NHS guidance on weight-management injections covers these contraindications in detail.

Cost context sometimes comes up alongside eligibility questions, the Mounjaro pricing page explains what private treatment typically costs and what an all-in price should cover. Understanding that is useful, but the clinical assessment comes first.

Can a young adult aged 18–25 use Mounjaro?

Yes, the licence begins at 18, and our guide to the age requirements for Mounjaro explains exactly how that lower boundary is applied in practice. A 19-year-old with a BMI of 32 and a diagnosis of hypertension is as eligible as a 45-year-old with the same profile, provided the prescriber's full assessment finds no contraindication. The clinical criteria do not favour one adult age group over another.

That said, younger adults sometimes present with different patterns of weight-related risk, and a good prescriber will want to understand the full picture: lifestyle context, any eating patterns that warrant careful attention, and realistic expectations about what the medicine can and cannot do alongside dietary changes. The practical guidance on getting the most from treatment is worth reading at any age. Newer research, including comparisons with other emerging medicines such as those discussed on the retatrutide comparison page, reinforces that no single agent suits everyone equally, and that the right choice depends on individual health factors, not headlines.

If you are 18 or over and want to understand whether you are clinically suitable, the straightforward next step is a free consultation with our prescribers.